94 related articles for article (PubMed ID: 17003348)
21. Epac2: a sulfonylurea receptor?
Rehmann H
Biochem Soc Trans; 2012 Feb; 40(1):6-10. PubMed ID: 22260657
[TBL] [Abstract][Full Text] [Related]
22. [Pharmacological and clinical profile of mitiglinide calcium hydrate (Glufast), a new insulinotropic agent with rapid onset].
Ojima K; Kiyono Y; Kojima M
Nihon Yakurigaku Zasshi; 2004 Oct; 124(4):245-55. PubMed ID: 15467258
[TBL] [Abstract][Full Text] [Related]
23. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels.
Stephan D; Winkler M; Kühner P; Russ U; Quast U
Diabetologia; 2006 Sep; 49(9):2039-48. PubMed ID: 16865362
[TBL] [Abstract][Full Text] [Related]
24. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
[TBL] [Abstract][Full Text] [Related]
25. The cytokine interleukin-1beta reduces the docking and fusion of insulin granules in pancreatic beta-cells, preferentially decreasing the first phase of exocytosis.
Ohara-Imaizumi M; Cardozo AK; Kikuta T; Eizirik DL; Nagamatsu S
J Biol Chem; 2004 Oct; 279(40):41271-4. PubMed ID: 15319424
[TBL] [Abstract][Full Text] [Related]
26. Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury.
Simard JM; Tsymbalyuk O; Ivanov A; Ivanova S; Bhatta S; Geng Z; Woo SK; Gerzanich V
J Clin Invest; 2007 Aug; 117(8):2105-13. PubMed ID: 17657312
[TBL] [Abstract][Full Text] [Related]
27. Taurine block of cloned ATP-sensitive K+ channels with different sulfonylurea receptor subunits expressed in Xenopus laevis oocytes.
Lim JG; Lee HY; Yun JE; Kim SP; Park JW; Suh SI; Jang BC; Cho CH; Bae JH; Kim SS; Han J; Park MJ; Song DK
Biochem Pharmacol; 2004 Sep; 68(5):901-10. PubMed ID: 15294453
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the rapidity of onset of the therapeutic effect between nateglinide and mitiglinide by PK/PD analysis in rats.
Takanohashi T; Arisaka H; Ubukata K; Hayashi M; Yamada Y
Eur J Drug Metab Pharmacokinet; 2012 Mar; 37(1):9-15. PubMed ID: 22012638
[TBL] [Abstract][Full Text] [Related]
29. Absence of exacerbation of myocardial stunning in anesthetized dogs treated with KAD-1229, a novel hypoglycemic agent.
Ichikawa K; Maruyama K; Murakami M; Tsuji A; Yamato T; Kusama H; Kojima M
Eur J Pharmacol; 2001 Nov; 431(3):331-8. PubMed ID: 11730726
[TBL] [Abstract][Full Text] [Related]
30. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase.
Takahashi A; Nagashima K; Hamasaki A; Kuwamura N; Kawasaki Y; Ikeda H; Yamada Y; Inagaki N; Seino Y
Diabetes Res Clin Pract; 2007 Sep; 77(3):343-50. PubMed ID: 17316868
[TBL] [Abstract][Full Text] [Related]
31. Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmachological properties and tissue selectivity.
Nagashima K; Takahashi A; Ikeda H; Hamasaki A; Kuwamura N; Yamada Y; Seino Y
Diabetes Res Clin Pract; 2004 Dec; 66 Suppl 1():S75-8. PubMed ID: 15563985
[TBL] [Abstract][Full Text] [Related]
32. Functional analysis of six Kir6.2 (KCNJ11) mutations causing neonatal diabetes.
Girard CA; Shimomura K; Proks P; Absalom N; Castano L; Perez de Nanclares G; Ashcroft FM
Pflugers Arch; 2006 Dec; 453(3):323-32. PubMed ID: 17021801
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the action of S 21403 (mitiglinide) on insulin secretion and biosynthesis in normal and diabetic beta-cells.
Kaiser N; Nesher R; Oprescu A; Efendic S; Cerasi E
Br J Pharmacol; 2005 Nov; 146(6):872-81. PubMed ID: 16158072
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of the glycaemic effects of sulfonylureas.
Ashcroft FM
Horm Metab Res; 1996 Sep; 28(9):456-63. PubMed ID: 8911983
[TBL] [Abstract][Full Text] [Related]
35. [Glimepiride].
Nakamura N
Nihon Rinsho; 2002 Sep; 60 Suppl 9():351-6. PubMed ID: 12387017
[No Abstract] [Full Text] [Related]
36. [Molecular basis of oral hypoglycemic sulfonylurea action].
Owecki M; Horst-Sikorska W; Sowiński J
Pol Merkur Lekarski; 2003 Nov; 15(89):445-8. PubMed ID: 14969140
[TBL] [Abstract][Full Text] [Related]
37. Rat homolog of sulfonylurea receptor 2B determines glibenclamide sensitivity of ROMK2 in Xenopus laevis oocyte.
Tanemoto M; Vanoye CG; Dong K; Welch R; Abe T; Hebert SC; Xu JZ
Am J Physiol Renal Physiol; 2000 Apr; 278(4):F659-66. PubMed ID: 10751228
[TBL] [Abstract][Full Text] [Related]
38. Sensitivity of Kir6.2-SUR1 currents, in the absence and presence of sodium azide, to the K(ATP) channel inhibitors, ciclazindol and englitazone.
McKay NG; Kinsella JM; Campbell CM; Ashford ML
Br J Pharmacol; 2000 Jun; 130(4):857-66. PubMed ID: 10864893
[TBL] [Abstract][Full Text] [Related]
39. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke.
Simard JM; Chen M; Tarasov KV; Bhatta S; Ivanova S; Melnitchenko L; Tsymbalyuk N; West GA; Gerzanich V
Nat Med; 2006 Apr; 12(4):433-40. PubMed ID: 16550187
[TBL] [Abstract][Full Text] [Related]
40. OATP1B3 is expressed in pancreatic β-islet cells and enhances the insulinotropic effect of the sulfonylurea derivative glibenclamide.
Meyer Zu Schwabedissen HE; Boettcher K; Steiner T; Schwarz UI; Keiser M; Kroemer HK; Siegmund W
Diabetes; 2014 Feb; 63(2):775-84. PubMed ID: 24150606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
